Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X. et al, (2019), Prostate, 79, 1079 - 1089

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review.

Sathianathen NJ. et al, (2019), BJU Int

DESNT: A Poor Prognosis Category of Human Prostate Cancer.

Luca B-A. et al, (2018), Eur Urol Focus, 4, 842 - 850

Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.

Bakht MK. et al, (2018), Endocr Relat Cancer, 26, 131 - 146

Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.

Bratt O. and Lamb AD., (2018), Eur Urol

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ. et al, (2018), Cochrane Database Syst Rev, 10

Pathologist Assessment of Novel Histological Features in Prostate Cancer

Tupper PM. et al, (2018), JOURNAL OF PATHOLOGY, 246, S42 - S42

Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis.

Philippou Y. et al, (2018), BJU Int

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L. et al, (2018), EBioMedicine, 31, 182 - 189

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer

Yang L. et al, (2018), EBIOMEDICINE, 31, 182 - 189

First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.

Lamb AD. et al, (2018), Eur Urol, 73, 653 - 655

Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Jurmeister S. et al, (2018), EMBO Mol Med, 10

Changing face of robot-assisted radical prostatectomy in Melbourne over 12 years.

Sathianathen NJ. et al, (2018), ANZ J Surg, 88, E200 - E203

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists’ perspective

Tan JL. et al, (2017), Urological Science, 28, 190 - 196

Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.

Hamdy FC. et al, (2017), Eur Urol

Orient Expression: Solving the Mystery of Asian Prostate Cancer?

Lamb AD. et al, (2017), Eur Urol

Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy.

Bellangino M. et al, (2017), Curr Urol Rep, 18

Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary.

Lamb AD. et al, (2017), Eur Urol Focus, 3, 328 - 329

Corrigendum to "Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals" [Eur. J. Oncol. Nurs. 29 (2017) 31-38].

Lamb AD. et al, (2017), Eur J Oncol Nurs, 30

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer

Sathianathen NJ. et al, (2017), Cochrane Database of Systematic Reviews, 2017

Load More

Include forthcoming?